Natera, Inc.

Natera, Inc. is a global leader in cell-free DNA (cfDNA) testing, dedicated to advancing personalized genetic testing and diagnostics across women's health, oncology, and organ health. Headquartered in Austin, Texas, with additional laboratory facilities in San Carlos, California, the company's mission is to transform disease management worldwide by providing earlier, more accurate, and actionable diagnostic information through innovative testing solutions.

Natera leverages its proprietary cfDNA technology platform, which combines advanced molecular biology techniques with bioinformatics software and artificial intelligence, to develop a comprehensive suite of diagnostic products. Key offerings in women's health include Panorama for non-invasive prenatal testing (NIPT), Horizon for carrier screening, and Empower for hereditary cancer screening. In oncology, the company provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) assessment and recurrence monitoring, alongside Altera for comprehensive genomic profiling and Latitude for tissue-free MRD testing. For organ health, Natera offers Prospera for transplant assessment and Renasight for kidney gene panel screening.

Under the leadership of CEO Steve Chapman, Natera continues to expand its market presence and clinical utility. Recent developments in 2026 include Signatera receiving Class C certification under the European Union's In Vitro Diagnostic Regulation (IVDR) and approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for colorectal cancer. The U.S. FDA also approved Signatera CDx as a companion diagnostic for muscle-invasive bladder cancer. The company has forged strategic partnerships, such as with Aveta Biomics for a Phase 3 clinical trial in head and neck cancer, and is actively investing in AI capabilities to enhance its diagnostic platforms. Natera maintains a strong market position in genetic testing, with analysts generally holding a "Moderate Buy" consensus rating for its stock, which trades on NASDAQ under the ticker NTRA.